CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Nature Reviews Drug Discovery
Original article

Lilly spends US$2.8 billion on psychedelic drugs for mental health

Positive
AI Analysis

Summary

Eli Lilly invests $2.8 billion in psychedelic drug development for mental health treatments. The acquisition represents a significant strategic move into the emerging psychedelic pharmaceutical space.

Importance:7/10
Sentiment:
0.60
acquisitionpsychedelicsmental healthinvestment
Related Companies

Read the original article

Published by Nature Reviews Drug Discovery on August 6, 2026 12:00 AM

Read Original